Form 4: C4 Therapeutics CFO Kendra Adams Reports Tax-Related Share Withholding
SEC Form 4 Filing
C4 Therapeutics' Chief Financial Officer, Kendra Adams, reports the withholding of shares to cover tax obligations related to vested restricted stock units.
Summary
- On September 18, 2024, Kendra Adams, the Chief Financial Officer of C4 Therapeutics, Inc. (CCCC), had 1,837 shares of common stock withheld by the issuer to satisfy tax obligations.
- This withholding occurred in connection with the vesting and settlement of restricted stock units.
- Following the transaction, Adams beneficially owns 81,791 shares of C4 Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a neutral event related to tax obligations on vested stock, with no inherent positive or negative implications for the company's performance.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders. This transaction reflects standard practice for covering tax liabilities associated with equity compensation.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine tax-related event.
Key Dates
| Date | Description |
|---|---|
| 09/18/2024 | Date of the transaction where shares were withheld to cover tax obligations. |
| 09/20/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.